MeDALL (Mechanisms of the Development of ALLergy): an integrated approach from phenotypes to systems medicine.

• Published in: Allergy
• Main Authors: Bousquet, J., Anto, J., Auffray, C., Akdis, M., Cambon-Thomsen, A., Keil, T., Haahtela, T., Lambrecht, B. N., Postma, D. S., Sunyer, J., Valenta, R., Akdis, C. A., Annesi-Maesano, Isabella, Arno, A., Bachert, C., Ballester, F., Basagana, X., Baumgartner, U., Bindslev-Jensen, C., Brunekreef, B., Carlsen, K. H., Chatzi, L., Crameri, R., Eveno, E., Forastiere, F., Garcia-Aymerich, J., Guerra, S., Hammad, H., Heinrich, J., Hirsch, D., Jacquemin, B., Kauffmann, F., Kerkhof, M., Kogevinas, M., Koppelman, G. H., Kowalski, M. L., Lau, S., Lodrup-Carlsen, K. C., Lopez-Botet, M., Lotvall, J., Lupinek, C., Maier, D., Makela, M. J., Martinez, F. D., Mestres, J., Momas, I., Nawijn, M. C., Neubauer, A., Oddie, S., Palkonen, S.
• Other Authors: Swiss Institute of Allergy and Asthma Research (SIAF), Universität Zürich Zürich = University of Zurich (UZH), Epidémiologie des maladies infectieuses et modélisation (ESIM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Département des Accélérateurs, de Cryogénie et de Magnétisme (ex SACM) (DACM), Institut de Recherches sur les lois Fondamentales de l'Univers (IRFU), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay, Environmental systems research, Universität Osnabrück - Osnabrück University, Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw - Poland-Faculté de Pharmacie de Paris, Public Hospital Medical Service, Ministry of Health Mozambique, Bousquet J, Anto J, R Valenta, CA Akdis, Annesi-Maesano I, Arno A, C Bachert, Ballester F, Basagana X, U Baumgartner, -Jensen C Bindslev, B Brunekreef, C Auffray, KH Carlsen, L Chatzi, R Crameri, E Eveno, Forastière F, Garcia-Aymerich J, S Guerra, H Hammad, Heinrich J, D Hirsch, Akdis M, Jacquemin B, Kauffmann F, M Kerkhof, M Kogevinas, GH Koppelman, Kowalski ML, S Lau, KC-Carlsen Lødrup, -M Botet Lopez, Lotvall J, Cambon-Thomsen A, C Lupinek, Maier D
• Format: Article in Journal/Newspaper
• Language: English
• Published: HAL CCSD 2011
• Subjects: [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie; karelian
• Online Access: https://hal.sorbonne-universite.fr/hal-00595853; https://doi.org/10.1111/j.1398-9995.2010.02534.x

International audience The origin of the epidemic of IgE-associated (allergic) diseases is unclear. MeDALL (Mechanisms of the Development of ALLergy), an FP7 European Union project (No. 264357), aims to generate novel knowledge on the mechanisms of initiation of allergy and to propose early diagnosis, prevention, and targets for therapy. A novel phenotype definition and an integrative translational approach are needed to understand how a network of molecular and environmental factors can lead to complex allergic diseases. A novel, stepwise, large-scale, and integrative approach will be led by a network of complementary experts in allergy, epidemiology, allergen biochemistry, immunology, molecular biology, epigenetics, functional genomics, bioinformatics, computational and systems biology. The following steps are proposed: (i) Identification of 'classical' and 'novel' phenotypes in existing birth cohorts; (ii) Building discovery of the relevant mechanisms in IgE-associated allergic diseases in existing longitudinal birth cohorts and Karelian children; (iii) Validation and redefinition of classical and novel phenotypes of IgE-associated allergic diseases; and (iv) Translational integration of systems biology outcomes into health care, including societal aspects. MeDALL will lead to: (i) A better understanding of allergic phenotypes, thus expanding current knowledge of the genomic and environmental determinants of allergic diseases in an integrative way; (ii) Novel diagnostic tools for the early diagnosis of allergy, targets for the development of novel treatment modalities, and prevention of allergic diseases; (iii) Improving the health of European citizens as well as increasing the competitiveness and boosting the innovative capacity of Europe, while addressing global health issues and ethical issues.